Kazunobu Suzuki1,2,3, Akira Watanabe1,2, Kenichiro Araki4,2, Takehiko Yokobori5,3, Norihumi Harimoto1, Dorgormaa Gantumur1, Kei Hagiwara1,2, Takahiro Yamanaka1,2, Norihiro Ishii1,2, Mariko Tsukagoshi1,2, Takamichi Igarashi1, Norio Kubo1,2, Navchaa Gombodorj6, Masahiko Nishiyama3,6, Yasuo Hosouchi7, Hiroyuki Kuwano2, Ken Shirabe1. 1. Department of Hepatobiliary and Pancreatic Surgery, Gunma University, Graduate School of Medicine, Maebashi, Japan. 2. Department of General Surgical Science, Gunma University, Graduate School of Medicine, Maebashi, Japan. 3. Research Program for Omics-based Medical Science, Division of Integrated Oncology Research, Gunma University Initiative for Advanced Research, Maebashi, Japan. 4. Department of Hepatobiliary and Pancreatic Surgery, Gunma University, Graduate School of Medicine, Maebashi, Japan karaki@gunma-u.ac.jp bori45@gunma-u.ac.jp. 5. Department of General Surgical Science, Gunma University, Graduate School of Medicine, Maebashi, Japan karaki@gunma-u.ac.jp bori45@gunma-u.ac.jp. 6. Department of Molecular Pharmacology and Oncology, Gunma University, Graduate School of Medicine, Maebashi, Japan. 7. Department of Surgery and Laparoscopic Surgery, Gunma Prefecture Saiseikai-Maebashi Hospital, Maebashi, Japan.
Abstract
BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is a leading cause of cancer-related deaths worldwide. Stathmin 1 (STMN1) suppression was reported to reduce cellular viability and migration potential. However, no previous studies have addressed whether STMN1 overexpression is associated with malignant potential in PDAC. MATERIALS AND METHODS: To clarify the clinical significance of STMN1 in PDAC, the STMN1 expression in 104 PDAC samples was evaluated by immunohistochemistry. Moreover, we evaluated the proliferative potential and migration ability of pancreatic cancer cell line Suit2 cells highly expressing STMN1. RESULTS: Cytoplasmic STMN1 were higher levels in PDAC than in corresponding non-cancerous tissues. PDAC patients with high STMN1 (n=29) were significantly associated with poor differentiation and distant metastasis compared to those with low STMN1 (n=75). The proliferation rates and migration ability in Suit2-STMN1 were higher than those of Suit2-mock. CONCLUSION: STMN1 evaluation could be a useful progression marker, and STMN1 may be a promising candidate for targeted therapies in PDAC. Copyright
BACKGROUND:Pancreatic ductal adenocarcinoma (PDAC) is a leading cause of cancer-related deaths worldwide. Stathmin 1 (STMN1) suppression was reported to reduce cellular viability and migration potential. However, no previous studies have addressed whether STMN1 overexpression is associated with malignant potential in PDAC. MATERIALS AND METHODS: To clarify the clinical significance of STMN1 in PDAC, the STMN1 expression in 104 PDAC samples was evaluated by immunohistochemistry. Moreover, we evaluated the proliferative potential and migration ability of pancreatic cancer cell line Suit2 cells highly expressing STMN1. RESULTS: Cytoplasmic STMN1 were higher levels in PDAC than in corresponding non-cancerous tissues. PDAC patients with high STMN1 (n=29) were significantly associated with poor differentiation and distant metastasis compared to those with low STMN1 (n=75). The proliferation rates and migration ability in Suit2-STMN1 were higher than those of Suit2-mock. CONCLUSION:STMN1 evaluation could be a useful progression marker, and STMN1 may be a promising candidate for targeted therapies in PDAC. Copyright
Authors: Katherine S Yang; Debora Ciprani; Aileen O'Shea; Andrew S Liss; Robert Yang; Sarah Fletcher-Mercaldo; Mari Mino-Kenudson; Carlos Fernández-Del Castillo; Ralph Weissleder Journal: Gastroenterology Date: 2020-12-07 Impact factor: 22.682
Authors: Scott Ferguson; Katherine S Yang; Piotr Zelga; Andrew S Liss; Jonathan C T Carlson; Carlos Fernandez Del Castillo; Ralph Weissleder Journal: Sci Adv Date: 2022-04-22 Impact factor: 14.957